Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients

CONCLUSION: Molecular subtype in breast cancer is an effective factor for predicting response to neoadjuvant chemotherapy. HER2-positive status was associated with high Ki-67 and high clinical and pathological response rate. Taxol needs to be added in neoadjuvant chemotherapy to improve pCR. Luminal subtypes respond poorly to chemotherapy.

Source: Indian Journal of Cancer - July 30, 2018 Category: Cancer & Oncology Authors: Shanmugam Subbiah Govindasamy Gopu P Senthilkumar P Muniasamy Source Type: research